This is a preview of subscription content, log in via an institution to check access.
Reference
Gil-Sierra MD, et al. Effectiveness of adalimumab in inflammatory bowel disease and influence of response to firstline treatment. European Journal of Hospital Pharmacy - Science and Practice 27 (Suppl. 1): A178 abstr. 5PSQ-062, Mar 2020. Available from: URL: http://doi.org/10.1136/ejhpharm-2020-eahpconf.379 [abstract]
Rights and permissions
About this article
Cite this article
Adalimumab/infliximab. Reactions Weekly 1829, 20 (2020). https://doi.org/10.1007/s40278-020-85610-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-85610-6